Features Partner Sites Information LinkXpress
Sign In
Demo Company

Peptide Mapping Columns Provide Faster, More Robust Performance

By BiotechDaily International staff writers
Posted on 21 May 2013
Print article
Image: The Agilent BioHPLC peptide mapping columns (Photo courtesy of Agilent Technologies).
Image: The Agilent BioHPLC peptide mapping columns (Photo courtesy of Agilent Technologies).
Image: The rapid resolution high definition Agilent ZORBAX RRHD 300-HILIC columns (Photo courtesy of Agilent Technologies).
Image: The rapid resolution high definition Agilent ZORBAX RRHD 300-HILIC columns (Photo courtesy of Agilent Technologies).
New high-performance peptide mapping-column solutions for HPLC and HILIC enable users to achieve results at exceptionally higher resolution and do it quicker.

Agilent Technologies Inc. (Santa Clara, CA, USA) has now introduced the latest upgrades to its “AdvancBio” family of columns for peptide mapping—the “BioHPLC” column and the “ZORBAX RRHD 300-HILIC” rapid resolution high definition for UHPLC column. These columns have been designed to deliver exceptional performance for the separation, characterization, and analysis of a wide range of proteins, monoclonal antibodies, peptides, and additional biologics. "We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed," said Anne Jones, Agilent's vice president and general manager for the chemistries business. "These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography."

The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity. In fact, it can produce exceptional analytical results 2 to 3 times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes. Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps. All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.

The AdvanceBio Peptide Mapping column is excellent for highly complex peptide mapping and will provide 100% sequence coverage of many protein digests, including rhEPO with 45 glycopeptide matches. These features are explored in the application note - High-Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column.

The ZORBAX RRHD 300-HILIC columns are the only sub 2-µm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities, and biopharmaceuticals. Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns. For 1.8 µm particles, the ZORBAX RRHD 300-HILIC columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC. These features are explored in the application note - Analysis of Erythropoietin Glycopeptides and Glycoforms by HILIC and RP Chromatography.

Related Links:

Agilent Technologies
AdvancBio Peptide Mapping Columns

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.